Serina Therapeutics, Inc.
SER
$3.81
-$0.09-2.31%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 116.00K | 130.00K | 51.00K | 56.00K | 3.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.00K | 130.00K | 51.00K | 56.00K | 3.16M |
| Cost of Revenue | 12.12M | 10.88M | 9.33M | 7.48M | 6.02M |
| Gross Profit | -12.00M | -10.75M | -9.27M | -7.42M | -2.87M |
| SG&A Expenses | 9.89M | 10.06M | 9.84M | 8.15M | 6.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.00M | 20.94M | 19.16M | 15.63M | 12.82M |
| Operating Income | -21.89M | -20.81M | -19.11M | -15.57M | -9.66M |
| Income Before Tax | -18.63M | -12.65M | -1.01M | -11.21M | -7.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.63 | -12.65 | -1.01 | -11.21 | -7.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 45.00K | 62.00K | 75.00K | 66.00K | 54.00K |
| Net Income | -18.59M | -12.59M | -939.00K | -11.14M | -7.35M |
| EBIT | -21.89M | -20.81M | -19.11M | -15.57M | -9.66M |
| EBITDA | -21.78M | -20.66M | -18.92M | -15.38M | -9.52M |
| EPS Basic | -2.19 | -1.58 | -0.31 | -5.20 | -4.18 |
| Normalized Basic EPS | -1.16 | -0.78 | 0.01 | -1.48 | -0.85 |
| EPS Diluted | -1.91 | -1.32 | -0.15 | -5.04 | -4.59 |
| Normalized Diluted EPS | -1.16 | -0.80 | -0.07 | -1.56 | -1.22 |
| Average Basic Shares Outstanding | 48.64M | 47.15M | 45.66M | 38.69M | 22.57M |
| Average Diluted Shares Outstanding | 48.64M | 49.05M | 49.20M | 42.23M | 30.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |